Regenics Board of Directors 2019

Tore Heldrup Rasmussen, MBA, Founder, Chairman of the Board. Mr. Rasmussen has been heading up several successful biotechnology companies prior to co-founding Regenics. Mr. Rasmussen brings many years of experience in strategy development and consumer products, as a Partner in MarkUp Consulting in Oslo and through tenures with Procter & Gamble and Orkla Foods (Norway). Mr. Rasmussen has an MBA degree from the University of Michigan.

Ola Røhte, Board member. Ola Røhte. Attorney-at-law and partner at Lynx law firm Oslo, with a degree from Oslo University and solid background as a commercial and maritime lawyer. His background also includes 20 years of independent work as an advisor and investor in his own advisory and investment firm as well as management and board positions, inter alia relating to the regulatory field  and securities placements. Previous engagements include investments and central roles in listed and unlisted companies, nationally and internationally, mainly within the shipping, offshore, finance, real estate, IT and biotech spaces. Focus on financial restructuring advisory services, mainly on the debt side to investors, banks, asset owners and issuers- company law, governance, regulatory and entrepreneurship.He was elected to the Board of Regenics AS in 2018.

Wilhelm Holst, Board member. Wilhelm Holst joined the Board of Regenics AS in 2018 alongside an investment in the company. He has extensive experience from the shipping industry, coming from CEO and COO roles at Lorentzen & Stemoco and RS Platou. Wilhem has through a long service in the Norwegian shipping industry added nextensive experience in Shipbroking and head of S&P roles. He now runs his own investment activity through Whl Invest and has additional Board positions in Aksel L Hansson AS, Flamier AS, High Seas AS and VotWear AS.


Philippe Collas, PhD, Founder, Director and Scientific Adviser. Dr. Collas has previously served on the Regenics Board of Directors. He is Professor at the Institute of Medical Biochemistry of the University of Oslo, Norway, where he directs a laboratory of 20 people. Dr. Collas holds an engineering degree from France and a PhD from the University of Massachusetts. He has tremendous experience in research on nuclear reprogramming from academia (University of Massachusetts, Amherst College, University of Oslo) and industry in the United States. He was a co-founder of Nucleotech LLC (USA) and has served as Consultant for several Biotech Companies in Europe, United States and Australia. He has developed cell-free systems to investigate nuclear dynamics and gene function and has published over 100 scientific articles in the area of nuclear reprogramming. He was the first to show that somatic cells can be reprogrammed using cellular extracts. Dr. Collas is member of the Norwegian Academy of Science and Letters.



Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.